Concordia Healthcare Corp (CXRX) : Montrusco Bolton Investments reduced its stake in Concordia Healthcare Corp by 3.93% during the most recent quarter end. The investment management company now holds a total of 1,812,262 shares of Concordia Healthcare Corp which is valued at $58,844,147 after selling 74,119 shares in Concordia Healthcare Corp , the firm said in a disclosure report filed with the SEC on Apr 19, 2016.Concordia Healthcare Corp makes up approximately 4.61% of Montrusco Bolton Investments’s portfolio.
Other Hedge Funds, Including , Simplex Trading sold out all of its stake in CXRX during the most recent quarter. The investment firm sold 1,100 shares of CXRX which is valued $26,367.
On the company’s financial health, Concordia Healthcare Corp reported $1.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Mar 23, 2016. Analyst had a consensus of $1.31. The company had revenue of $191.90 million for the quarter, compared to analysts expectations of $187.36 million. The company’s revenue was up 385.8% compared to the same quarter last year.
Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.